应答者与非应答者:如何预测GLP-1或GLP-1/GIP受体激动剂治疗的应答
本叙述性综述检索PubMed至2026年5月25日,汇总2型糖尿病血糖控制、超重或肥胖者减重及两者兼有的双重代谢获益三种临床情境下,GLP-1受体激动剂和GLP-1/GIP双受体激动剂应答差异的预测因素。结论认为尚无单一基线特征能可靠预测应答,早期治疗中应答是目前最可操作的个体化依据,遗传、代谢和微生物标志物需前瞻性重复验证后才能临床应用。
要点
- 肥胖无糖尿病者应答异质性最明显,减重不足5%的应答不佳者在对照试验中约占10%。
- 2型糖尿病血糖应答不佳较少见但具临床意义,早期治疗中应答是目前最可操作的预测因素。
- GLP1R变异与减重疗效及胃肠道耐受性相关,GIPR变异与替尔泊肽恶心呕吐相关,均为假说生成性、尚未重复。
核心结论
- 尚无单一基线特征能可靠预测应答,早期治疗中应答的结构化评估是目前个体化治疗最可辩护的依据。
- 遗传、代谢和微生物标志物需前瞻性重复验证后才能临床应用。
研究设计与样本
- 叙述性综述,检索PubMed至2026年5月25日,限定英文、人体研究、2005至2026年。
- 证据按三种临床情境组织:2型糖尿病血糖控制、无2型糖尿病的超重或肥胖者减重、同时具备两种疾病者的双重代谢获益。
主要发现
- 应答异质性在无糖尿病的肥胖者中最明显,应答不佳通常定义为总体重减轻小于5%,在对照试验中约影响10%的参与者,真实世界队列提示常规实践中比例更高。
- 2型糖尿病中血糖应答不佳较少见,但具有临床意义。
- 近期一项大型全基因组关联研究报告GLP1R药物靶点基因变异与减重疗效及胃肠道耐受性相关,药物特异性GIPR变异与替尔泊肽所致恶心和呕吐相关。
- 上述遗传学发现基于自我报告、单一队列且尚未重复,仍属假说生成性,而非个体水平基因分型的依据。
- 代谢、微生物组和神经内分泌预测因素处于同等初步阶段。
关键数值与推荐
- 应答不佳常用定义:总体重减轻小于5%。
- 在对照试验中,减重不足5%的应答不佳者约占10%的参与者。
临床怎么用
- 目前最可辩护的个体化治疗依据是对早期治疗中应答进行结构化评估。
- 遗传、代谢和微生物标志物需前瞻性重复验证后才能应用于临床。
局限性
- GLP1R与GIPR相关发现基于自我报告、单一队列且尚未重复,仍属假说生成性。
- 代谢、微生物组和神经内分泌预测因素处于同等初步阶段。
- 遗传、代谢和微生物标志物需前瞻性重复验证后才能临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. Methods Narrative review. PubMed was searched to 25 May 2026 (English language, human studies, 2005–2026) for biological, genetic, metabolic, hormonal, behavioural and psychosocial predictors of differential response. Evidence is organised across three clinically distinct contexts: glycaemic control in T2D; weight loss in people with overweight or obesity without T2D; and dual metabolic benefit in those with both conditions. Results Response heterogeneity is most pronounced in obesity without diabetes, where non-response—commonly defined as less than 5% total body weight loss—affects approximately 10% of participants in controlled trials, with real-world cohorts suggesting a higher frequency in routine practice; glycaemic non-response in T2D is less common but clinically significant. Across all three contexts, early on-treatment response is the most readily actionable predictor currently available. A recent large genome-wide association study reported associations between variation in the GLP1R drug-target gene and both weight-loss efficacy and gastrointestinal tolerability, and between agent-specific GIPR variants and nausea and vomiting with tirzepatide; these self-reported, single-cohort and as-yet unreplicated findings remain hypothesis-generating rather than a basis for individual-level genotyping. Metabolic, microbiome and neuroendocrine predictors are at a comparably preliminary stage. Conclusion No single baseline characteristic reliably predicts response. Structured assessment of early on-treatment response is currently the most defensible basis for individualising therapy; genetic, metabolic and microbiome markers require prospective replication before clinical application.
引用
- Diabetes, Obesity and Metabolism:Responders Vs. Non‐Responders or How to Predict the Response to GLP‐1 or GLP‐1/GIP Receptor Agonist Therapy
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。